查詢結果分析
相關文獻
- The HGF/c-Met/COX-2 and Jagged1/Notch1/COX-2 Pathways as Molecular Targets for Gastric Cancer Treatment
- Intraluminal Mucin Pool in Mucinous Gastric Adenocarcinoma: A Case Report
- 胃癌之流行病學特徵及危險因子
- Dispute of Extended Lymph Node Dissection for Gastric Cancer
- 源自胃癌的克魯根堡氏瘤:十年臨床經瞼
- Serum Hepatocyte Growth Factor Levels in Patients with Inflammatory Lung Diseases
- 胃癌化學治療之進展
- Pregnancy Associated with Gastric Carcinoma
- 20-MHz Ultrasonic Probe to Identify Early Gastric Cancer Suitable for Endoscopic Mucosal Resection
- 胃癌復發併吸收不良症候群
頁籤選單縮合
題 名 | The HGF/c-Met/COX-2 and Jagged1/Notch1/COX-2 Pathways as Molecular Targets for Gastric Cancer Treatment=HGF/c-Met/COX-2和Jagged1/Notch1/COX-2路徑為胃癌治療之分子標靶 |
---|---|
作 者 | 宋懿宸; 黃國宏; 宋明達; 戚謹文; | 書刊名 | 臺灣癌症醫學雜誌 |
卷 期 | 1:2 2014.09[民103.09] |
頁 次 | 頁93-102 |
分類號 | 416.243 |
關鍵詞 | 肝細胞生長因子; 胃癌; Hepatocyte growth factor; c-Met; Jagged1; Notch1; COX-2; Gastric cancer; |
語 文 | 英文(English) |
中文摘要 | 在 2012 年的台灣,胃癌在所有癌症死亡率中排名第五位。雖然在最近的數十年間, 胃癌的病患數量逐年遞減,但其在全世界的癌症死亡率中仍是排名第二。因此,迫切地 需要發展更多具有潛力的分子標靶和治療方式來治療胃癌病患。臨床上,COX-2 的大量 表現與胃癌的轉移、侵犯和血管新生有高度地關係。在胃癌中也發現 COX-2 和 c-Met (或Jagged1)的表現量呈現正相關。在許多研究中也指出,HGF/c-Met 和 Jagged1/Notch1 路 徑能促進 COX-2 的表現,進而促進胃癌細胞的生長、移動和侵犯。最近,針對 HGF/c-Met 路徑已設計有許多單株抗體或受體酪氨酸激酶抑制劑,且在許多臨床試驗顯示出有治療 胃癌之潛力。因此,此文章整合了 HGF/c-Met/COX-2 和 Jagged1/Notch1/COX-2 路徑的 分子機制,以及最新的胃癌標靶治療。 |
英文摘要 | In Taiwan, gastric cancer ranked fifth in total cancer mortality in 2012. Although the number of gastric cancer cases has declined in recent decades, it is still the second leading cause of cancer mortality worldwide. Therefore, more potential molecular targets and therapeutic options for gastric cancer treatment are urgently needed. The overexpression of COX-2 has been shown to be highly associated with metastasis, invasion and angiogenesis of gastric cancer. A positive correlation between COX-2 and c-Met (or Jagged1) expression also has been found in gastric cancer. Moreover, several studies indicated that hepatocyte growth factor (HGF)/c-Met and Jagged1/Notch1 pathways can up-regulate COX-2 expression, resulting in increased cell growth, migration and invasion in gastric cancer cells. Recently, various monoclonal antibodies or receptor tyrosine kinase inhibitors have been designed to target HGF/c-Met pathway and have shown potentials for gastric cancer therapy in clinical trials. In this article, we have summarized the molecular mechanisms of HGF/c-Met/COX-2 and Jagged1/Notch1/COX-2 pathways, and the latest target therapies for gastric cancer. |
本系統中英文摘要資訊取自各篇刊載內容。